Lates News

Every AI Express, Huatai Securities released a research report on November 5th, giving Xi'an Juchu Pharmaceutical (002332.SZ) a "buy" rating. The main reasons for the rating include: 1) the prices of raw materials in the domestic and international markets have declined slightly, putting pressure on short-term business; 2) some formulated products have seen a decline in revenue due to the impact of centralized procurement, while new products such as Yousiyue are growing rapidly. (Daily Economic News)